Abnormalities in glutamate neurotransmission may have a role in the pathophysiology of adolescent depression. The present pilot study examined changes in cortical glutamine/glutamate ratios in depressed adolescents receiving high-frequency repetitive transcranial magnetic stimulation. Ten adolescents with treatment-refractory major depressive disorder received up to 30 sessions of 10-Hz repetitive transcranial magnetic stimulation at 120% motor threshold with 3000 pulses per session applied to the left dorsolateral prefrontal cortex. Baseline, posttreatment, and 6-month follow-up proton magnetic resonance spectroscopy scans of the anterior cingulate cortex and left dorsolateral prefrontal cortex were collected at 3 T with 8-cm 3 voxels. Glutamate metabolites were quantified with 2 distinct proton magnetic resonance spectroscopy sequences in each brain region. After repetitive transcranial magnetic stimulation and at 6 months of follow-up, glutamine/glutamate ratios increased in the anterior cingulate cortex and left dorsolateral prefrontal cortex with both measurements. The increase in the glutamine/ glutamate ratio reached statistical significance with the TE-optimized PRESS sequence in the anterior cingulate cortex. Glutamine/glutamate ratios increased in conjunction with depressive symptom improvement. This reached statistical significance with the TE-optimized PRESS sequence in the left dorsolateral prefrontal cortex. High-frequency repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex may modulate glutamate neurochemistry in depressed adolescents.
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Introduction
Major depressive disorder (MDD) frequently presents in adolescence and is often recalcitrant to treatment (Brent, 2009) which leads to substantial morbidity, mortality, and a societal financial burden (Blazer et al., 1994; Greenberg et al., 2015) . Suicide is a leading cause of death in adolescents and a stark reminder that the current mechanistic understanding of depression is underdeveloped (Vitiello et al., 2011) . Unfortunately, antidepressant medications, cognitive-behavioral therapy, and combined treatment are either ineffective or have minimal durability for most depressed adolescents (March et al., 2009) . Noninvasive brain stimulation technologies such as repetitive transcranial magnetic stimulation (rTMS) may have promise as enduring therapeutic interventions in young people (Donaldson et al., 2014) . Prior research has shown that rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) is a safe and effective treatment for MDD in adults who fail to benefit from antidepressant medications (O'Reardon et al., 2007; George et al., 2010) . Initial open-label studies of rTMS for MDD in adolescents suggest that it may be effective and well-tolerated in younger people, as well (Donaldson et al., 2014) . Although rTMS treatment has US Food and Drug Administration clearance for adults, little is known about its mechanism of action and target engagement, especially in adolescents. Further research focused on 
